Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Two OptiMSM Studies Accepted for Publication


Studies

Two OptiMSM Studies Accepted for Publication

VANCOUVER, Wash.--Cardinal Nutrition announced that two studies on its MSM ingredient, OptiMSM™, are scheduled for publication in scientific journals in the coming months.

The first study was accepted for publication in the Journal of Food and Chemical Toxicology. Researchers at the Southern Research Institute in Birmingham, Ala., in cooperation with researchers from the Institute for Drug Research and Pharmaceutical Control and Development Laboratory in Budapest, Hungary, performed the two-part acute toxicity study. In the first part, 20 rats were given a single oral dose of 2 g of MSM per kg of body weight (equivalent to a single human dose not exceeding 140 g). No mortality was observed and no adverse effects or clinical signs of toxicity were observed in any of the rats or in any organs and tissues that were examined.

In part two, the researchers performed a 90-day subchronic oral toxicity study where 80 rats were given 1,500 mg/kg/d of MSM for 90 days. This is equivalent to more than 100 g/d for a person weighing 150, where the recommended intake is 2 g/d to 10 g/d. No deaths and no toxic symptoms occurred in this part either.

The second study involving OptiMSM was accepted for publication in the April 2002 issue of the Journal of Alternative and Complementary Medicine (www.liebertpub.com). The study revealed that OptiMSM, a sulfur-based compound, helps people with seasonal allergic rhinitis (hay fever). This study was a collaboration between the GENESIS Center for Integrative Medicine and the American Institute for Biosocial and Medical Research. Fifty subjects with a diagnosis of seasonal allergic rhinitis completed the open-label study. Each subject took 2,600 mg/d of OptiMSM for 30 days. Within the first week, subjects reported improvement in allergy symptoms and continued improvement throughout the study period.

For more information, visit www.cardinalmsm.com or Booth #1601-1603 at SupplySide East.

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish